Seeing Is Believing
Currently out of the existing stock ratings of Michael King, 107 are a BUY (98.17%), 2 are a HOLD (1.83%).
Analyst Michael King, carries an average stock price target met ratio of 44.36% that have a potential upside of 30.21% achieved within 152 days. Previously, Michael King worked at HCWAINWRIGHT.
Michael King’s has documented 206 price targets and ratings displayed on 23 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on SONN, Sonnet Biotherapeutics Holdings at 22-Aug-2023.
Analyst best performing recommendations are on BMEA (BIOMEA FUSION).
The best stock recommendation documented was for BMEA (BIOMEA FUSION) at 3/24/2023. The price target of $22 was fulfilled within 4 days with a profit of $6.57 (42.58%) receiving and performance score of 106.45.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$495
$34.54 (7.50%)
$345
11 days ago
(06-Oct-2025)
18/19 (94.74%)
$43 (9.51%)
240
Hold
$475
$14.54 (3.16%)
$268
11 days ago
(06-Oct-2025)
10/11 (90.91%)
$23 (5.09%)
39
Buy
$500
$39.54 (8.59%)
$330
28 days ago
(19-Sep-2025)
23/24 (95.83%)
$46.44 (10.24%)
209
Buy
$520
$59.54 (12.93%)
$359
1 months ago
(17-Sep-2025)
10/11 (90.91%)
$68.27 (15.11%)
142
Buy
$566
$105.54 (22.92%)
$370
1 months 1 days ago
(16-Sep-2025)
8/10 (80%)
$104.76 (22.71%)
289
What Year was the first public recommendation made by Michael King?